Horizon Cancer: Pragmatic Immunotherapy Trials
Funds three pragmatic clinical trials, €7-8M each, testing existing cancer immunotherapies in real-world care for patients whose disease resists treatment.
Cancer patients whose disease doesn't respond to standard treatment — refractory cancer, at any stage, any subtype, any age — need better access to immunotherapy that's actually tailored to them. Immunotherapy research has produced real treatment options, but Europe's oncology systems are fragmented, costs are rising, and a lot of that promise doesn't reach routine care in a way that's affordable …
Running randomised or cluster-randomised, academic investigator-initiated pragmatic clinical trials that test immunotherapeutic interventions for patients with refractory cancers — any subtype, any stage, any age group — to find out what works best in real-world care, not just under ideal trial conditions. Primary and secondary endpoints (overall survival, patient-reported outcomes, quality of life) have to be defined together with patients and caregivers, and results have to be broken down by sex, gender, age and factors like socio-economic status or ethnicity. Biomarker-informed patient stratification and analysis of the trial's own data are the only translational research in scope — there's no separate track for developing new therapeutics, biomarkers or diagnostics. The consortium has to bring a genuine mix of disciplines and sectors, including regional or national health authorities as partners, and successful projects join the EU Cancer Mission's 'Diagnosis and Treatment' project cluster.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up